Alzamend Neuro, Inc.

Alzamend Neuro, Inc. is a clinical-stage biopharmaceutical company that develops new products to treat Alzheimer's disease, bipolar disorder (BD), major depressive disorder (MDD), and post-traumatic stress disorder (PTSD). The company has two product candidates and aims to bring treatments or potential cures to market. Alzheimer's disease is a primary focus, affecting approximately 7.4 million Americans, a number projected to increase to 13 million individuals by 2050. It is the fifth leading cause of death in the U.S. as of 2024. Current Alzheimer's treatments offer temporary symptom relief, and while one treatment has shown to slow disease progression, none have been shown to halt it. The disease also impacts over 13 million Americans who provide an estimated 19 billion hours of unpaid care annually. In 2026, the estimated healthcare costs for treating individuals with Alzheimer's in the U.S. are expected to be $409 billion, including $263 billion in Medicare and Medicaid payments. These costs could reach $1 trillion per year by 2050 if no permanent treatment or cure is discovered.